These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 20153897

  • 1. Thiopurine S-methyltransferase gene polymorphism and 6-mercaptopurine dose intensity in Indian children with acute lymphoblastic leukemia.
    Kapoor G, Sinha R, Naithani R, Chandgothia M.
    Leuk Res; 2010 Aug; 34(8):1023-6. PubMed ID: 20153897
    [Abstract] [Full Text] [Related]

  • 2. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.
    Peregud-Pogorzelski J, Tetera-Rudnicka E, Kurzawski M, Brodkiewicz A, Adrianowska N, Mlynarski W, Januszkiewicz D, Drozdzik M.
    Pediatr Blood Cancer; 2011 Oct; 57(4):578-82. PubMed ID: 21319286
    [Abstract] [Full Text] [Related]

  • 3. Thiopurine S-methyltransferase (TPMT) gene polymorphism in Brazilian children with acute lymphoblastic leukemia: association with clinical and laboratory data.
    Silva MR, de Oliveira BM, Viana MB, Murao M, Romanha AJ.
    Ther Drug Monit; 2008 Dec; 30(6):700-4. PubMed ID: 19057372
    [Abstract] [Full Text] [Related]

  • 4. Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia.
    Dokmanovic L, Urosevic J, Janic D, Jovanovic N, Petrucev B, Tosic N, Pavlovic S.
    Ther Drug Monit; 2006 Dec; 28(6):800-6. PubMed ID: 17164697
    [Abstract] [Full Text] [Related]

  • 5. The low frequency of defective TPMT alleles in Turkish population: a study on pediatric patients with acute lymphoblastic leukemia.
    Tumer TB, Ulusoy G, Adali O, Sahin G, Gozdasoglu S, Arinç E.
    Am J Hematol; 2007 Oct; 82(10):906-10. PubMed ID: 17617792
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?
    Fakhoury M, Andreu-Gallien J, Mahr A, Medard Y, Azougagh S, Vilmer E, Jacqz-Aigrain E.
    J Clin Pharm Ther; 2007 Dec; 32(6):633-9. PubMed ID: 18021342
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia.
    Donnan JR, Ungar WJ, Mathews M, Hancock-Howard RL, Rahman P.
    Pediatr Blood Cancer; 2011 Aug; 57(2):231-9. PubMed ID: 21344614
    [Abstract] [Full Text] [Related]

  • 14. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon.
    Zgheib NK, Akika R, Mahfouz R, Aridi CA, Ghanem KM, Saab R, Abboud MR, Tarek N, El Solh H, Muwakkit SA.
    Pediatr Blood Cancer; 2017 Jan; 64(1):146-150. PubMed ID: 27577869
    [Abstract] [Full Text] [Related]

  • 15. Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine.
    Wan Rosalina WR, Teh LK, Mohamad N, Nasir A, Yusoff R, Baba AA, Salleh MZ.
    J Clin Pharm Ther; 2012 Apr; 37(2):237-41. PubMed ID: 21545474
    [Abstract] [Full Text] [Related]

  • 16. Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.
    Hawwa AF, Collier PS, Millership JS, McCarthy A, Dempsey S, Cairns C, McElnay JC.
    Br J Clin Pharmacol; 2008 Dec; 66(6):826-37. PubMed ID: 18823306
    [Abstract] [Full Text] [Related]

  • 17. Application of SNaPshot for analysis of thiopurine methyltransferase gene polymorphism.
    Kapoor G, Maitra A, Somlata, Brahmachari V.
    Indian J Med Res; 2009 May; 129(5):500-5. PubMed ID: 19675376
    [Abstract] [Full Text] [Related]

  • 18. The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment.
    Coulthard SA, Matheson EC, Hall AG, Hogarth LA.
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1385-91. PubMed ID: 15571264
    [Abstract] [Full Text] [Related]

  • 19. Thiopurine methyltransferase in acute lymphoblastic leukaemia: biochemical and molecular biological aspects.
    Brouwer C, De Abreu RA, Keizer-Garritsen JJ, Lambooy LH, Ament K, ter Riet PG, van Wering ER, Trijbels FJ, Veerman AJ, Hoogerbrugge PM, Bökkerink JP.
    Eur J Cancer; 2005 Mar; 41(4):613-23. PubMed ID: 15737567
    [Abstract] [Full Text] [Related]

  • 20. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
    Stocco G, Crews KR, Evans WE.
    Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.